Key result
Orodispersible tablets dissolve within seconds without water to improve antihypertensive adherence, with perindopril ODTs increasing adherence scores from 2.76 to 3.57.
Why the study?
Population-level blood pressure control has plateaued due to poor adherence, particularly among elderly, pediatric, and dysphagic patients facing barriers to swallowing daily tablets. This review critically appraises the real-world utility and formulation challenges of orodispersible tablets in hypertensive care.
Do antihypertensive orodispersible tablets improve medication adherence and blood pressure control compared to conventional tablets in patients with hypertension?
Do antihypertensive orodispersible tablets improve medication adherence and blood pressure control compared to conventional tablets in patients with hypertension?
Answers are grounded in this paper and cite their sources.
Orodispersible tablets offer a promising, patient-centered formulation strategy to overcome swallowing difficulties and improve medication adherence in hypertension management, though manufacturing, stability, and regulatory challenges currently limit widespread clinical adoption.
Population-level blood pressure control has hit a frustrating plateau over the past decade, and surprisingly, the bottleneck is seldom pharmacological potency-it is adherence. For the elderly, pediatric patients, and those with neurological or age-related swallowing difficulties, the mundane act of taking a daily tablet presents a genuine functional barrier that directly undermines treatment continuity. Orodispersible Tablets (ODTs), which dissolve on the tongue within seconds without water, present a conceptually simple yet remarkably effective answer to this problem. This review seeks to move beyond the usual textbook summary of ODT formulations and instead critically appraises their real-world utility in hypertensive care. From a formulation standpoint, the engineering challenges are more intricate than they first appear. Achieving a disintegration time under 30 sec is relatively straightforward; doing so while adequately masking the intensely bitter taste of drugs like amlodipine or telmisartan, and maintaining sufficient mechanical strength to survive packaging and handling, is where most prototypes fail. The literature points to layered approaches-combining superdisintegrants such as crospovidone with ion-exchange resin complexes-as the most promising route, though the added complexity often translates into manufacturing costs that discourage commercial uptake. More recent work on co-processing these excipients with solid dispersion technologies further addresses the poor aqueous solubility that plagues many newer ARBs, offering a dual advantage that conventional tablets cannot match. Clinically, the evidence tilts favorably. Perindopril ODTs, for instance, have shown reliable efficacy in blunting the early-morning systolic surge, a well-established trigger for cerebrovascular events. However, the translational chasm between laboratory innovation and pharmacy shelves remains concerningly wide; issues related to hygroscopicity, batch-tobatch reproducibility, and a lack of standardized pharmacopoeial guidelines for ODTs continue to hinder widespread adoption. This review ultimately contends that ODTs are not a mere gimmick for patient convenience, but a strategic tool that could redefine therapeutic success in hypertension-provided the field pivots toward practical scalability and cost-conscious design. Pairing ODT platforms with fixed-dose combinations or emerging 3D-printed personalization could finally close the adherence gap, but only if formulation scientists, clinicians, and health economists begin collaborating at the earliest stages of development rather than in retrospect.
No takes yet. Share an insight, caveat, or question.
Nagineni et al. (2026) conducted a review in Hypertension. Antihypertensive Orodispersible Tablets (ODTs) vs. Conventional oral tablets was evaluated. Orodispersible tablets dissolve within seconds without water to improve antihypertensive adherence, with perindopril ODTs increasing adherence scores from 2.76 to 3.57.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: